Sanofi - Contingent Value Rig (GCVRZ)

[Enterprising Investor]

Sanofi announces settlement agreement related to Contingent Value Rights (CVRs) Litigation (10/31/19)

PARIS – October 31, 2019 - Sanofi announced today that it has entered into an agreement to settle (the “Settlement Agreement”) the previously disclosed action UMB Bank, N.A., as Trustee v. Sanofi (No. 15 Civ. 8725 (GBD) (the “Action”), currently pending in the United States District Court for the Southern District of New York. The Action involves claims against Sanofi for breach of the Contingent Value Rights Agreement, dated as of March 31, 2011 (the “CVR Agreement”), relating to Sanofi’s publicly-traded contingent value rights (“CVRs”) issued in connection with the acquisition of Genzyme Corporation.

The Settlement Agreement provides that Sanofi and Plaintiff UMB Bank, N.A. (“Plaintiff” or the “Trustee”), on behalf of an express trust for the benefit of each and every holder of one or more contingent value rights (the “CVR Holders”), have agreed to fully and completely resolve the Action, without any admission of liability or wrongdoing, on the following terms:

In full and complete satisfaction of all claims asserted in the Action and in exchange for the releases set forth in the Settlement Agreement, Sanofi shall pay to the Trustee, for distribution as discussed below, a total of $315,000,000 U.S.D. (the “Settlement Payment” or “Litigation Proceeds”);

Any and all claims or causes of action that (a) in any way arise out of, are based upon, relate to, or concern the facts, matters, occurrences, claims made, allegations, representations, omissions, actions (or failure to act), transactions, agreements, or conduct alleged, complained of, set forth, referred to, involved in, or which could have been raised or made in the Action and/or any of the complaints in the Action, (b) in any way arise out of, are based upon, relate to, or concern the CVR Agreement and/or the CVRs, (c) in any way relate to or concern the development and/or commercialization of alemtuzumab (marketed under the brand name Lemtrada®), and/or (d) in any way relate to or concern the production and/or manufacturing of Cerezyme® and/or Fabrazyme®, shall be released;

The following events shall take place: (i) the Action will be voluntarily dismissed with prejudice; (ii) the CVRs will be delisted from the NASDAQ, will not thereafter be listed on any national securities exchange or quotation in any other quotation medium, and will be extinguished; and (iii) the CVR Agreement, and each and all of its attendant rights and obligations, will be terminated.
The occurrence of the Effective Date (as defined in the Settlement Agreement) of the Settlement Agreement is subject to, among other conditions, Court Approval (as defined in the Settlement Agreement) and, in accordance with the terms of the Settlement Agreement, the Trustee intends to initiate proceedings in the probate court for Hennepin County, Minnesota (the “Probate Court”), pursuant to the Minnesota Trust Code, Minn. Stat. §§ 501C.0201-.0208 seeking an order from the Probate Court, among other things, (i) approving the Settlement Agreement and directing the implementation of its terms, (ii) providing that the CVR Agreement is terminated and that none of the Trustee, the CVR Holders, and Sanofi shall have any further rights or obligations under the CVR Agreement, (iii) approving the notice(s) sent by the Trustee to the CVR Holders in connection with the Settlement Agreement and the court approval thereof and providing that such notice(s) satisfy any and all notice requirements relating to court approval and as set forth in the CVR Agreement, including, for the avoidance of doubt, those imposed on Sanofi, and (iv) providing that Sanofi shall have no responsibility to anyone, including the CVR Holders, relating to the Trustee’s distribution of the Settlement Payment. Sanofi cannot predict when or if the Effective Date of the Settlement Agreement will occur. If the Effective Date does not occur, the parties will return to the positions they were in with respect to the Action prior to entry into the Settlement Agreement.

Plaintiff, in its capacity as Trustee for the CVR Holders, is solely responsible for the distribution of the Settlement Payment to CVR Holders.

The Trustee previously entered into an agreement with certain CVR Holders (the “Funding Holders”), dated November 16, 2016, through which it, subject to certain terms and conditions, obtained funding for the prosecution of the Action (the “Funding Agreement”). In accordance with the terms of the CVR Agreement and the Funding Agreement, prior to any distribution to be made to all CVR Holders, any Litigation Proceeds will first go towards repaying the Funding Holders for their funded amounts, to the expenses of the Trustee, including legal fees and expenses and the Trustee’s fees, and to a success fee paid to the Funding Holders and to counsel for the Trustee equal in aggregate to the greater of (a) half of the legal fees incurred on a contingent basis plus the total funding commitment of the Funding Holders and (b) an amount ranging between approximately 20% and 27% of the gross Litigation Proceeds, depending on the total amount of Litigation Proceeds (all such fees, expenses and other payments required to be made from the Litigation Proceeds in accordance with the Funding Agreement, the “Funding Agreement Payments”). After the Funding Agreement Payments, 100% of the remaining Litigation Proceeds shall be distributed by the Trustee for the benefit of all CVR Holders in accordance with the CVR Agreement.

The Trustee currently estimates that the Funding Agreement Payments will total approximately $107,000,000. As a result, the Trustee currently estimates that approximately $208,000,000 of the Litigation Proceeds, or approximately $0.88 per CVR, will be distributed to CVR Holders on account of the outstanding CVRs. However, as of the date hereof, the Trustee is unable to determine the precise amount that will be distributed to the CVR Holders (on an aggregate or per CVR basis).

For any questions relating to the Settlement Agreement and/or the distribution of the Settlement Payment, Sanofi directs all CVR Holders to the Trustee:

Gavin Wilkinson, Senior Vice President
UMB Bank, National Association
120 South Sixth Street, Suite 1400
Minneapolis, MN 55402
Email: [e-mail]

The above description of the Settlement Agreement is a summary of the material terms only, and is qualified in its entirety by the terms thereof. The Settlement Agreement is attached as an Exhibit to a Form 6-K being filed substantially contemporaneously herewith.

The Settlement Payment will not have an impact on Sanofi’s business net income.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

https://www.globenewswire.com/news-release/2019/10/31/1938440/0/en/Sanofi-announces-settlement-agreement-related-to-Contingent-Value-Rights-CVRs-Litigation.html

[greendragon-]

It's been a long time since anyone has posted here. Another increase, haven't seen it at this price since 2014.

[Enterprising Investor]

New Findings In The GCVRZ Lawsuit (10/02/18)

https://seekingalpha.com/instablog/5978721-ruerd-heeg/5219209-new-findings-gcvrz-lawsuit

[Enterprising Investor]

U.S. District Court
Southern District of New York (Foley Square)
Civil Case #: 1:15-08725

[JHOGG]

Why the volume? What the $ run up? Any answers out there?!? Legal decision in favor of stock holder? Revenue increase approaching milestone payout?!? What's up???

[pennystockaholic]

Up 8% turn around is coming $$$$$$$$$$

[pennystockaholic]

I like these levels, we will see a strong push soon.

[JHOGG]

Over 7M in volume this week. What's your guess?!?

[JHOGG]

Lemtrada Targets Circulating Innate Immune Cells in RRMS Patients

https://multiplesclerosisnewstoday.com/2016/11/03/lemtrada-targets-circulating-innate-immune-cells-rrms-relapsing-remitting-multiple-sclerosis

[JHOGG]

E.investor

Can you provide some insight into what all this means for shareholders?

Many thanks!

[Enterprising Investor]

Amended Discovery Plan and Scheduling Order (10/24/16)

Amended Pleadings due by 1/17/2017.

Joinder of Parties due by 1/17/2017.

Fact Discovery due by 8/11/2017.

Deposition due by 2/2/2018.

Pretrial Order due by 3/16/2018

Source: PACER [Docket 84]

[Enterprising Investor]

Notice of Interlocutory Appeal Order on Motion for Partial Summary Judgment. Document filed by UMB Bank, N.A., as Trustee.

U.S. Court of Appeals, Second Circuit

Source: PACER [Docket 81]

[Enterprising Investor]

Deadline for PSMs 2, 3 and 4 is 12/31/20

pg 4

[Enterprising Investor]

Memorandum Decision and Order: Denying Motion for Partial Summary Judgment; Granting Motion to Dismiss (9/08/16)

Defendant's Motion to Dismiss Count II, the Breach of Contract claim based upon missing PSM #1, is DENIED. Defendant's Motion to Dismiss Count III is GRANTED. Plaintiff's claim for Breach of the Covenant of Good Faith and Fair Dealing is dismissed as duplicative of its breach of contract claims. Plaintiff's Motion for Summary Judgment seeking immediate payment of attorney's fees and other expenses is DENIED with prejudice ORDERED.

Signed by Judge George B. Daniels on 9/08/2016.

Source: PACER [Docket 76]

[Enterprising Investor]

Order Granting Motion to Substitute Party (7/19/16)

Plaintiff's unopposed motion to substitute UMB Bank, N.A., as Trustee, for Plaintiff American Stock Transfer & Trust Company, LLC is Granted. The Clerk of Court is directed to change the caption on this action to reflect the above substitution and close the motion at ECF No. 56. American Stock Transfer & Trust Company LLC (as Trustee) terminated.

Signed by Judge George B. Daniels on 7/19/2016.

Source: PACER [Docket 66]

[JHOGG]

Volume!!!!!

[JHOGG]

Yep!!!!

$$$$

[pcarew]

Sales Milestone #2 **might** actually be achievable!

Based upon the latest sales results ( http://tinyurl.com/ha9wnkc ),
the USA Q over Q growth rate is running at ~11% and the rest of the world ~9%

To achieve #2, ($1.8B global sales over 4 quarters ) a growth rate of ~7% is needed.

Maybe, just maybe this could happen. Could be one of the facts behind the recent rise in CVR value.

[TERIA]

Smithers Rapra have forecast the global market for Pre-Filled Syringes to rise to $6.6 Billion by 2020. Good news for Sanofi!

Excited to hear more insight from the Senior Director of their PFS platform - Paolo Mangiagalli, when he presents in Central London at Pre-Filled Syringes Europe.

Details on the event in Jan 2017 are available at http://www.pre-filled-syringes.com/ihub

[JHOGG]

Blog: Federal Court Gives Teeth to Operational Efforts Covenant in Sanofi/Genzyme Earn-Out Dispute

9/27/2016



http://www.jdsupra.com/legalnews/blog-federal-court-gives-teeth-to-91464/

[Enterprising Investor]

Treatment Effects Maintained Over Six Years in Patients with Relapsing Remitting Multiple Sclerosis who Received Sanofi Genzyme’s Lemtrada® (alemtuzumab) in Clinical Trials (9/16/15)

– At six years in the extension of two Phase III pivotal studies, 64 and 55 percent of Lemtrada-treated patients received no additional Lemtrada in the prior five years –

– Consistent effects seen across relapse, disability, brain atrophy and MRI lesion activity –

PARIS--(BUSINESS WIRE)--Sanofi and its specialty care global business unit Sanofi Genzyme announced today positive new six-year investigational data from the extension study of Lemtrada® (alemtuzumab) in patients with relapsing remitting multiple sclerosis (RRMS). These results will be presented today at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in London.

In RRMS patients treated with Lemtrada in the CARE-MS Phase III pivotal studies, the effects described below observed in the two-year trials were maintained through four additional years in the extension study. More than 90 percent of the patients who were treated with Lemtrada in the CARE-MS trials enrolled in the extension. These patients were eligible to receive additional treatment with Lemtrada in the extension if they experienced at least one relapse or at least two new or enlarging brain or spinal cord lesions.

After the initial two courses of treatment in the CARE-MS trials, which were given at month zero and at month 12, 64 percent of Lemtrada patients from CARE-MS I and 55 percent from CARE-MS II did not receive additional Lemtrada treatment during the following five years, through month 72.

The low annualized relapse rates observed in patients who received Lemtrada in the Phase III studies CARE-MS I (0.16) and CARE-MS II (0.28) remained consistent throughout the extension (0.12 and 0.15 at year six.)

Through year six, 77 percent and 72 percent of patients who received Lemtrada in CARE-MS I and CARE-MS II, respectively, did not experience worsening of six-month confirmed disability as measured by the Expanded Disability Status Scale (EDSS).

Through year six, 34 percent and 43 percent of patients who had disability before receiving Lemtrada in CARE-MS I and CARE-MS II, respectively, had improvement in EDSS score confirmed over at least six months as compared with pre-treatment baseline.

Through year six, patients who received Lemtrada in CARE-MS I and II experienced a slowing of brain atrophy as measured by brain parenchymal fraction on magnetic resonance imaging (MRI). In years three through six, the median yearly brain volume loss was -0.20 percent or less, which was lower than what was observed in the Lemtrada-treated patients during the two-year pivotal studies (CARE-MS I: -0.59 percent in year one; -0.25 percent in year two; CARE-MS II: -0.48 percent in year one; -0.22 percent in year two).

In each of years three, four, five and six, most patients had no evidence of MRI disease activity, defined as no new gadolinium-enhancing T1 lesions and no new or enlarging T2 lesions (66 – 72 percent, CARE-MS I; 68 – 70 percent, CARE-MS II).

Through year six, the yearly incidence of most adverse events during the extension study was comparable or reduced compared with the pivotal studies. The frequency of thyroid adverse events was highest in year three and declined thereafter.

“The Lemtrada data being presented at ECTRIMS from the ongoing extension study illustrate that more than half of patients experienced sustained effects of treatment on disease activity, despite receiving their last treatment course five years previously,” said Dr. Alasdair Coles, Professor, Department of Clinical Neurosciences, University of Cambridge. “It is very promising to see these consistent effects over time across relapse, disability and MRI measures.”

The Phase III trials of Lemtrada were randomized, rater-blinded, two-year pivotal studies comparing treatment with Lemtrada to high-dose subcutaneous interferon beta-1a in patients with RRMS who had active disease and were either new to treatment (CARE-MS I) or who had an inadequate response to another therapy (CARE-MS II). Active disease was defined as at least two relapses in the previous two years and at least one in the previous year. The protocol called for Lemtrada to be administered as two annual treatment courses, with the first treatment course administered via intravenous infusion on five consecutive days, and the second course administered on three consecutive days, 12 months later.

In clinical trials, serious side effects associated with Lemtrada included infusion reactions, autoimmune disorders (such as thyroid disease, autoimmune cytopenias, and nephropathies), infections and pneumonitis. Lemtrada may cause an increased risk of malignancies. Risk management programs incorporating education and monitoring help support early detection and management of key identified and potential risks. The most common side effects of Lemtrada are rash, headache, pyrexia, nasopharyngitis, nausea, urinary tract infection, fatigue, insomnia, upper respiratory tract infection, herpes viral infection, urticaria, pruritus, thyroid gland disorders, fungal infection, arthralgia, pain in extremity, back pain, diarrhea, sinusitis, oropharyngeal pain, paresthesia, dizziness, abdominal pain, flushing, and vomiting. (See Important Safety Information below.)

About Lemtrada® (alemtuzumab)

Lemtrada is approved in more than 50 countries, with additional marketing applications under review by regulatory authorities globally. Lemtrada is supported by a comprehensive and extensive clinical development program that involved nearly 1,500 patients worldwide and 5,400 patient-years of follow-up. More than 9,200 patients have been treated with Lemtrada commercially worldwide.

The precise mechanism by which alemtuzumab exerts its therapeutic effects in MS is unknown. Alemtuzumab is a monoclonal antibody that targets CD52, a protein abundant on T and B cells. Circulating T and B cells are thought to be responsible for the damaging inflammatory process in MS. Lemtrada depletes circulating T and B lymphocytes after each treatment course. Lymphocyte counts then increase over time with a reconstitution of the lymphocyte population that varies for the different lymphocyte subtypes.
Sanofi Genzyme holds the worldwide rights to alemtuzumab and has responsibility for its development and commercialization in multiple sclerosis. Bayer Healthcare receives contingent payments based on global sales revenue.

Lemtrada® (alemtuzumab) U.S. Indication

LEMTRADA is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS). Because of its risks, LEMTRADA is generally used in people who have tried 2 or more MS medicines that have not worked well enough. It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.

Do not receive LEMTRADA if you are infected with human immunodeficiency virus (HIV).

IMPORTANT SAFETY INFORMATION

LEMTRADA can cause serious side effects including:
Serious autoimmune problems: Some people receiving LEMTRADA develop a condition where the immune cells in your body attack other cells or organs in the body (autoimmunity), which can be serious and may cause death. Serious autoimmune problems may include:

• Immune thrombocytopenia, which is when reduced platelet counts in your blood cause severe bleeding that, if not treated, may cause life-threatening problems. Call your healthcare provider right away if you have any of the following symptoms: easy bruising; bleeding from a cut that is hard to stop; heavier menstrual periods than normal; bleeding from your gums or nose that is new or takes longer than usual to stop; small, scattered spots on your skin that are red, pink, or purple

• Kidney problems called anti-glomerular basement membrane disease, which can, if untreated, lead to severe kidney damage, kidney failure that needs dialysis, a kidney transplant, or death. Call your healthcare provider right away if you have any of the following symptoms: blood in the urine (red or tea-colored urine); swelling of legs or feet; coughing up blood
It is important for you to have blood and urine tests before you receive, while you are receiving and every month, for 4 years or longer, after you receive your last LEMTRADA infusion.
Serious infusion reactions: LEMTRADA can cause serious infusion reactions that may cause death. Serious infusion reactions may happen while you receive, or up to 24 hours or longer after you receive LEMTRADA.

• You will receive your infusion at a healthcare facility with equipment and staff trained to manage infusion reactions, including serious allergic reactions, and urgent heart or breathing problems. You will be watched while you receive, and for 2 hours or longer after you receive, LEMTRADA. If a serious infusion reaction happens while you are receiving LEMTRADA, your infusion may be stopped.

Tell your healthcare provider right away if you have any of the following symptoms of a serious infusion reaction during the infusion, and after you have left the healthcare facility:

• swelling in your mouth or throat

• fast, slow, or irregular heartbeat

• trouble breathing

• chest pain

• weakness

• rash

To lower your chances of getting a serious infusion reaction, your healthcare provider will give you a medicine called corticosteroids before your first 3 infusions of a treatment course. You may also be given other medicines before or after the infusion to try to reduce your chances of having these reactions or to treat them after they happen.

Certain cancers: Receiving LEMTRADA may increase your chance of getting some kinds of cancers, including thyroid cancer, skin cancer (melanoma), and blood cancers called lymphoproliferative disorders and lymphoma. Call your healthcare provider if you have the following symptoms that may be a sign of thyroid cancer:

• new lump

• trouble swallowing or breathing

• swelling in your neck

• cough that is not caused by a cold

• pain in front of neck

• hoarseness or other voice changes that do not go away
Have your skin checked before you start receiving LEMTRADA and each year while you are receiving treatment to monitor for symptoms of skin cancer.

Because of risks of autoimmunity, infusion reactions, and some kinds of cancers, LEMTRADA is only available through a restricted program called the LEMTRADA Risk Evaluation and Mitigation Strategy (REMS) Program.

Thyroid problems: Some patients taking LEMTRADA may get an overactive thyroid (hyperthyroidism) or an underactive thyroid (hypothyroidism). Call your healthcare provider if you have any of these symptoms:

• excessive sweating

• unexplained weight gain

• unexplained weight loss

• feeling cold

• eye swelling

• worsening tiredness

• nervousness

• constipation

• fast heartbeat

Low blood counts (cytopenias): LEMTRADA may cause a decrease in some types of blood cells. Some people with these low blood counts have increased infections. Call your doctor right away if you have symptoms of cytopenias such as:

• weakness

• dark urine

• chest pain

• fast heartbeat

• yellowing of the skin or whites of the eyes (jaundice)
Serious infections: LEMTRADA may cause you to have a serious infection while you receive and after receiving a course of treatment. Serious infections may include:

• Herpes viral infections. Some people taking LEMTRADA have an increased chance of getting herpes viral infections. Take any medicines as prescribed by your healthcare provider to reduce your chances of getting these infections.

• Tuberculosis. Your healthcare provider should check you for tuberculosis before you receive LEMTRADA.

• Hepatitis. People who are at high risk of, or are carriers of, hepatitis B (HBV) or hepatitis C (HCV) may be at risk of irreversible liver damage.

These are not all the possible infections that could happen while on LEMTRADA. Call your healthcare provider right away if you have symptoms of a serious infection such as fever or swollen glands. Talk to your healthcare provider before you get vaccinations after receiving LEMTRADA. Certain vaccinations may increase your chances of getting infections.

Swelling of lung tissue (pneumonitis): Some people have had swelling of the lung tissue while receiving LEMTRADA. Call your healthcare provider right away if you have the following symptoms:

• shortness of breath

• chest pain or tightness

• cough

• coughing up blood

• wheezing

Before receiving LEMTRADA, tell your healthcare provider if you:

• are taking a medicine called Campath® (alemtuzumab)

• have bleeding, thyroid, or kidney problems

• have HIV

• have a recent history of infection

• have received a live vaccine in the past 6 weeks before receiving LEMTRADA or plan to receive any live vaccines. Ask your healthcare provider if you are not sure if your vaccine is a live vaccine

• are pregnant or plan to become pregnant. LEMTRADA may harm your unborn baby. You should use birth control while receiving LEMTRADA and for 4 months after your course of treatment

• are breastfeeding or plan to breastfeed. You and your healthcare provider should decide if you should receive LEMTRADA or breastfeed. You should not do both.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. LEMTRADA and other medicines may affect each other, causing side effects. Especially tell your healthcare provider if you take medicines that increase your chance of getting infections, including medicines used to treat cancer or to control your immune system.

The most common side effects of LEMTRADA include:

• rash

• headache

• thyroid problems

• fever

• swelling of your nose and throat

• nausea

• urinary tract infection

• feeling tired

• trouble sleeping

• upper respiratory infection

• herpes viral infection

• hives

• itching

• fungal infection

• joint pain

• pain in your arms or legs

• back pain

• diarrhea

• sinus infection

• mouth pain or sore throat

• tingling sensation

• dizziness

• stomach pain

• sudden redness in face, neck, or chest

• vomiting

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of LEMTRADA.

You are encouraged to report side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088
Please see full U.S. Prescribing Information, including boxed WARNING and Medication Guide.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families. Learn more at www.sanofigenzyme.com

Sanofi® is a registered trademark of Sanofi. Genzyme® and Lemtrada® are registered trademarks of Genzyme Corporation. All rights reserved.

http://www.businesswire.com/news/home/20160915006516/en/Real-Industry-Appoints-Michael-Hobey-Chief-Financial

[JHOGG]

Boom! Volume!!! Whose acquiring big blocks and what do they know?!?

[JHOGG]

2.7M volume! PPS holding. Assume acquiring thanking place. For Q2 revenue expectation? For legal decision in support of shareholders? Or something else?!?

[JHOGG]

Q1 double digit growth topping $100M. What will Q2 bring?!? What are the odds they'll hit at least 1 sales milestone?!?

http://www.bizjournals.com/boston/blog/bioflash/2016/04/sanofi-genzyme-sees-20-percent-growth-in-sales-in.html

[JHOGG]

Someone bought 1M shares! Someone in the know I presume!

[JHOGG]

Another 1M+ trading day!!!!

[Enterprising Investor]

Any recovery for CVR holders will more likely come from legal action rather than the result of increasing product sales.

Time is running out. Lemtrada is expected to lose patent protection in September 2017.

Thus, the reason why American Stock Transfer & Trust Company LLC as trustee filed suit.

[JHOGG]

Strong volume last two days. 2015 revenue $243M. Q1 revenue $88M. Could there be another jump for Q2 revenue? Pushing us toward $400M payout milestone??? Thoughts?!?

[Enterprising Investor]

Action over the last few months does not appear retail.

[JHOGG]

Lemtrada Offers Long-Term Stability in MS Patients.

Great news. More usage! But also should provide more support for legal case against Sanofi.



http://www.medpagetoday.com/meetingcoverage/cmsc/58313

[JHOGG]

Consistently creeping up.....

Keep it rolling.

As it becomes available, please post any information/news/data/thoughts on the positive interest and increase in PPS.

[CrownCannabis]

Honestly im just catching up, been going through the filings and realized its no longer relevant. It is kind of confusing..

Thanks

[JHOGG]

Easy Frank. I appreciate EI's insight. I've been a bit confused with a few of your posts that are based on Sanofi diabetes products which are irrelevant to the CVRs.

[CrownCannabis]

It was the pre-market trade that went through.

Im not sure why E.I. would be better suited than me

[JHOGG]

Was this the yesterday morning trade cancelled or an additional trade of 20M that was cancelled?!? If the later could be a Sanofi buy back but they weren't using the proper channels and/or paperwork and therefore needed to cancel. Thoughts E.I.????

[CrownCannabis]

20M share trade cancelled in after hrs

http://www.nasdaq.com/symbol/gcvrz/after-hours

[CrownCannabis]

SCHEDULE 14A---06/01/2016


http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=11422178&RcvdDate=6/1/2016&CoName=MEDIVATION%2C%20INC.&FormType=DFAN14A&View=html

[CrownCannabis]

Interesting..

Marked you #200

[JHOGG]

My thought as well. If Sanofi is expecting a payout they possibly are scooping up shares in the cheap. Think about it....buy 20M at $.19 = $4M versus paying out $2-$4 at $40-$80M. Pretty nice savings!

[Enterprising Investor]

American Stock Transfer & Trust Company LLC recently resigned as trustee.

By resigning, it can now force Sanofi to pay all of its fees and expenses, including the costs of the CVR lawsuit. Pretty smart?

Sanofi wants to see how things play out. Of course, they do.

American Stock Transfer & Trust Company LLC is seeking a Speedy Hearing Pursuant to FRCP 57.

In addition, no successor trustee has been named by Sanofi.

Numerous letters from both counsels have been sent to Judge Daniels in the past two weeks.

I am not sure how the CVR compensation portion of the lawsuit will progress once American no longer acts as trustee. It is possible that an investor group is buying up CVRs in advance of playing a role similar to the Colonial BancGroup case.

Or, maybe Sanofi is buying up CVRs in the open market? Not sure it can be done without a tender offer.

[CrownCannabis]

GOOGLE INVOLVED

http://finance.yahoo.com/video/google-looks-cures-140000650.html

[CrownCannabis]

This is gonna go through the roof..

[CrownCannabis]

http://mediaroom.sanofi.com/fda-advisory-committee-recommends-approval-of-sanofi-treatment-for-adults-with-type-2-diabetes/

[db7]

09:27:06 20,240,462 @ .19

[CrownCannabis]

Pre-market? Could you check trades to see at what price? Thanks..

265k On the bid looks great..

[JHOGG]

Can someone help me understand a 20M share purchase this morning?!?

[Defkon]

Seems like a few good postings about lemtrada. If I buy in now can I still earn from those earning marks?

http://www.kcrg.com/content/news/New-Drug-Being-Used-to-Treat-Multiple-Sclerosis-371415421.html

http://www.forbes.com/sites/matthewherper/2016/03/08/what-ted-cruz-gets-wrong-about-the-fda-tough-regulation-can-spark-innovation/#67ebb5bc2861

http://www.wndu.com/content/news/A-new-drug-may-stop-and-reverse-multiple-sclerosis--370960351.html

[JHOGG]

Any predictions on the upcoming appeals judgement?

You think Sanofi will be held liable for any wrong doing? If so, predicted value of judgement? If no, why?

[JHOGG]

Reach out to the following:

Richard A. Maniskas, Esquire
Ryan & Maniskas, LLP
995 Old Eagle School Rd., Ste. 311
Wayne, PA 19087
(P) 484-588-5516
(F) 484-450-2582
www.rmclasslaw.com

[Enterprising Investor]

American Stock Transfer & Trust Company LLC as trustee is representing our interests.